|
Session 82
Poster Abstracts
HIV Vaccines: Clinical Trials and Mathematical Models of Efficacy
Monday, 1:30 - 3:30 pm
Poster Hall |
| 475 |
Vaccination with MVA Nef Is Immunogenic and Safe in HIV-1-negative Volunteers
Thomas Harrer*1, P Chaplin2, J Hain1, J Vollmar2, B Petzold2, A Handley2, S Bergmann1, K Eismann1, M Rittmaier1, and E Harrer1
1Univ Hosp, Erlangen, Germany and 2Bavarian Nordic, Martinsried, Germany |
| 476 |
A Randomized Open Phase I Trial to Assess the Safety and Immunogenicity of 4 mg DNA-C followed by NYVAC-C Compared with NYVAC-C alone in Healthy HIV-negative Volunteers
Pierre-Alexandre Bart*1, T Barber2, M Khonkarly1, D Ciuffreda1, S Burnet1, W Stöhr3, M Cowen2, S McCormack3, G Pantaleo1, J Weber2, and EuroVacc Programme
1Ctr Univ Hosp Vaudois, Lausanne, Switzerland; 2Imperial Coll, London, UK; and 3Med Res Council Clin Trials Unit, London, UK |
| 477 |
Recognition of Autologous HIV-1 Variants by CTL in HIV-1-infected Subjects after Vaccination with an MVA-Nef Vector
Thomas Harrer*1, M Bäuerle1, P Chaplin2, J Hain2, B Petzold2, K Eismann1, S Bergmann1, M Rittmaier1, S Müller1, and E Harrer1
1Univ Hosp, Erlangen, Germany and 2Bavarian Nordic, Martinsried, Germany |
| 478 |
Clinical Safety of HIV Lipopeptides Used as Vaccines in Healthy Volunteers and HIV-infected Adults
Christine Durier*1, O Launay2, V Meiffrédy1, Y Saïdi1, D Salmon2, Y Lévy3, J G Guillet4, G Pialoux5, and J P Aboulker1
1INSERM SC10, Villejuif, France; 2Hosp Cochin, Paris, France; 3Hosp Henri Mondor, Creteil, France; 4INSERM U567, Paris, France; and 5Hosp Tenon, Paris, France |
479
 |
Predicting the Effect of a Partially Effective HIV Vaccine and Subsequent Risk Behavior Change on the Heterosexual HIV Epidemic in Developing Countries: A South African Example
Kyeen Mesesan*1, D Owens2, E Vardas3, G Gray3, J McIntyre3, and D Paltiel1
1Yale Univ, New Haven, CT, US; 2VA HlthCare System & Stanford Univ, Palo Alto, CA, US; and 3University of the Witwatersrand, Johannesburg, South Africa |
480
|
Estimating the Benefit of a HIV-1 Vaccine that Reduces Viral Load Set-point
Swati Gupta*1, L Jacobson2, C Rinaldo3, J Phair4, B Jamieson5, J Margolick2, D Mehrotra1, M Robertson1, and W Straus1
1Merck Res Labs, West Point, PA, US; 2Johns Hopkins Univ, Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3Univ of Pittsburgh, Graduate Sch of Publ Hlth, PA, US; 4Northwestern Univ Med Sch, Chicago, IL, US; and 5Univ of California Sch of Publ Hlth, Los Angeles, US |
| 481 |
Efficacy of Intradermal Administration of Hepatitis B Vaccine in HIV-infected Non-responders to 2 Courses of Intramuscular HBV Vaccine
Stephen Shafran*, L Mashinter, A Lindemulder, G Taylor, and I Chiu
Univ of Alberta, Edmonton, Canada |
|
